Pfizer’s Stock May Be Heading For A Big Breakout (NYSE:PFE)

Pfizer (NYSE:PFE) has undoubtedly been getting plenty of attention in recent months, with the potential for the company to make a coronavirus vaccine. It is well known that the company is partnering with BioNTech (NASDAQ:BNTX), to work on this vaccine.

A trader sees some positive news flow coming for Pfizer, betting that the stock will rise 7% by the middle of October. Additionally, the technical chart is suggesting that the stochastics rise as well. You can track all of my SA articles on this Google Spreadsheet.

Boosting Estimates

Pfizer stock has undoubtedly caught a sizable move higher, rising by more than 40% from its March lows. But that ride has been bumpy at best, with the shares plunging by as much as 19% in June. Even with the prospect of a vaccine, analysts do not see much benefit going to the company in 2020, with revenue forecast to fall by 4.3% to $49.5 billion.

However, the benefit is likely to come in 2021, with revenue forecast to rebound by 9.8% in 2021 to $54.3 billion. Analysts have been raising their revenue forecasts for the company as well. For example, on July 12, analysts had been forecasting revenue of $50.8 billion.

Earnings in 2020 are expected to be weak and fall by about 1% to $2.93 per share. However, those earnings are forecast to rebound by 13.9% in 2021 to $3.34 per share.

Even with the shares moving sharply higher in recent months, the stock trades at just 11.6 times next year’s earnings estimates, which is at the low end of the historical range and below the average of 13.0 over the past two years.

Betting on Big Gains

The bullish outlook and favorable valuation are likely driving some traders to bet the shares continue to advance. On August 24, the open interest levels for the October 16 $40 strike price calls rose by 31,108 contracts. The options traded on the ASK and were bought for around $1.22 per contract. It implies that stock is trading around $41.25 or higher by the expiration date.

Technical Strength

The chart is also suggesting the shares continue to rise. There is a bullish pennant that has formed on the chart. That type of pattern is a continuation pattern and indicates the stock may rise to around $45. Additionally, the relative strength index is trending higher as well, suggesting the recent strength in Pfizer should continue.

The significant risk to the bull narrative laid out above is if the company should the vaccine trial fail. This would damage the ability for the stock to rise and likely cause to reverse lower. Additionally, disappointing results would likely cause analysts to reduce their revenue and earnings outlook for the company, thus making the shares more expensive.

Whether the data is positive or negative, Pfizer’s stock is likely to move over the near term.

Love this article? Then hit the follow button at the top of the story!

Let The Market Be Your Guide

Finding the next big move in the market is never easy, so let us help you determine what that move will be. Every day, Reading The Market uses changes in fundamentals, technicals, and options markets to determine the next significant move in stocks, sectors, and indexes.

To Find Out More Visit Our Home Page

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and, unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.

Be the first to comment

Leave a Reply

Your email address will not be published.